{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T09:27:05Z","timestamp":1779010025594,"version":"3.51.4"},"reference-count":28,"publisher":"American Society for Microbiology","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin. Vaccine Immunol."],"published-print":{"date-parts":[[2013,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>In Madrid, Spain, the 13-valent pneumococcal conjugate vaccine (PCV13) replaced PCV7 in the pediatric universal vaccination calendar in June 2010. A prospective clinical surveillance that included all children hospitalized with culture- and\/or PCR-confirmed invasive pneumococcal disease (IPD) was performed in all Madrid hospitals. The incidence rates (IRs) (defined as the number of cases\/100,000 inhabitants aged &lt;15 years) in the PCV7 (May 2007 to April 2010) versus PCV13 (May 2011 to April 2012) periods were compared. There were 499 cases in the PCV7 period and 79 cases in the PCV13 period. Globally, the IR significantly decreased from 17.09 (PCV7 period) to 7.70 (PCV13 period), with significant decreases (PCV7 versus PCV13 periods) in all age groups for bacteremic pneumonia (5.51 versus 1.56), parapneumonic pneumococcal empyema (PPE) (5.72 versus 3.12), and meningitis (2.16 versus 0.97). In the PCV13 period, significant reductions (the IR in the PCV7 period versus the IR in the PCV13 period) were found in IPDs caused by PCV13 serotypes (13.49 versus 4.38), and specifically by serotypes 1 (globally [4.79 versus 2.53], for bacteremic pneumonia [2.23 versus 0.97], and for PPE [2.26 versus 1.17]), serotype 5 (globally [1.88 versus 0.00], for bacteremic pneumonia [0.89 versus 0.00], and for PPE [0.55 versus 0.00]), and serotype 19A (globally [3.77 versus 0.49], for bacteremic pneumonia [0.72 versus 0.00], for PPE [0.89 versus 0.00], and for meningitis [0.62 versus 0.00]). IPDs caused by non-PCV13 serotypes did not increase (IR, 3.60 in the PCV7 period versus 3.31 in the PCV13 period), regardless of age or presentation. No IPDs caused by the PCV13 serotypes were found in children who received 3 doses of PCV13. The number of hospitalization days and sanitary costs were significantly lower in the PCV13 period. The switch from PCV7 to PCV13 in the universal pediatric vaccination calendar provided sanitary and economical benefits without a replacement by non-PCV13 serotypes.<\/jats:p>","DOI":"10.1128\/cvi.00239-13","type":"journal-article","created":{"date-parts":[[2013,8,8]],"date-time":"2013-08-08T06:23:24Z","timestamp":1375943004000},"page":"1524-1530","source":"Crossref","is-referenced-by-count":46,"title":["Expansion of Serotype Coverage in the Universal Pediatric Vaccination Calendar: Short-Term Effects on Age- and Serotype-Dependent Incidence of Invasive Pneumococcal Clinical Presentations in Madrid, Spain"],"prefix":"10.1128","volume":"20","author":[{"given":"Juan","family":"Picazo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesus","family":"Ruiz-Contreras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Casado-Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagrario","family":"Negreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria-Jesus","family":"Garc\u00eda-de-Miguel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Hern\u00e1ndez-Sampelayo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Otheo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"M\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","published-online":{"date-parts":[[2013,8,7]]},"reference":[{"key":"key20180919073709_B1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1128\/CVI.00317-10","article-title":"Relationship between serotypes, age, and clinical presentation of invasive pneumococcal disease in Madrid, Spain, after introduction of the 7-valent pneumococcal conjugate vaccine into the vaccination calendar","volume":"18","author":"Heracles Study Group","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"key20180919073709_B2","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.vaccine.2010.12.114","article-title":"Clonal and clinical profile of Streptococcus pneumoniae serotype 19A causing pediatric invasive infections: a 2-year (2007-2009) laboratory-based surveillance in Madrid","volume":"29","author":"Picazo","year":"2011","journal-title":"Vaccine"},{"key":"key20180919073709_B3","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/INF.0b013e31820a418a","article-title":"Laboratory-based, 2-year surveillance of pediatric parapneumonic pneumococcal empyema following heptavalent pneumococcal conjugate vaccine universal vaccination in Madrid","volume":"30","author":"HERACLES Study Group","year":"2011","journal-title":"Pediatr. Infect. Dis. J."},{"key":"key20180919073709_B4","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/INF.0b013e31827e8594","article-title":"Impact of introduction of conjugate vaccines in the vaccination schedule on the incidence of pediatric invasive pneumococcal disease requiring hospitalization in Madrid 2007 to 2011","volume":"32","author":"Picazo","year":"2013","journal-title":"Pediatr. Infect. Dis. J."},{"key":"key20180919073709_B5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/648593","article-title":"Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine","volume":"201","author":"Active Bacterial Core Surveillance\/Emerging Infections Program Network","year":"2010","journal-title":"J. Infect. Dis."},{"key":"key20180919073709_B6","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/INF.0b013e31824de9f6","article-title":"The worldwide impact of the seven-valent pneumococcal conjugate vaccine","volume":"31","author":"Fitzwater","year":"2012","journal-title":"Pediatr. Infect. Dis. J."},{"key":"key20180919073709_B7","doi-asserted-by":"publisher","first-page":"e39927","DOI":"10.1371\/journal.pone.0039927","article-title":"Mathematical modelling long-term effects of replacing Prevnar7 with Prevnar13 on invasive pneumococcal diseases in England and Wales","volume":"7","author":"Choi","year":"2012","journal-title":"PLoS One"},{"key":"key20180919073709_B8","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1016\/j.ijid.2009.05.010","article-title":"Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines","volume":"14","author":"Isaacman","year":"2010","journal-title":"Int. J. Infect. Dis."},{"key":"key20180919073709_B9","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1586\/erv.12.68","article-title":"Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults","volume":"11","author":"Gladstone","year":"2012","journal-title":"Expert Rev. Vaccines"},{"key":"key20180919073709_B10","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1128\/JCM.39.4.1553-1558.2001","article-title":"Simultaneous detection of Neisseria meningitidis, Haemophilus influenzae, and Streptococcus pneumoniae in suspected cases of meningitis and septicemia using real-time PCR","volume":"39","author":"Corless","year":"2001","journal-title":"J. Clin. Microbiol."},{"key":"key20180919073709_B11","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1128\/JCM.02498-06","article-title":"Evaluation and improvement of real-time PCR assays targeting lytA, ply, and psaA genes for detection of pneumococcal DNA","volume":"45","author":"Carvalho","year":"2007","journal-title":"J. Clin. Microbiol."},{"key":"key20180919073709_B12","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1128\/JCM.01651-09","article-title":"Direct serogrouping of Streptococcus pneumoniae strains in clinical samples by use of a latex agglutination test","volume":"48","author":"Sanz","year":"2010","journal-title":"J. Clin. Microbiol."},{"key":"key20180919073709_B13","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1099\/00221287-144-11-3049","article-title":"A multilocus sequence typing scheme for Streptococcus pneumoniae: identification of clones associated with serious invasive disease","volume":"144","author":"Enright","year":"1998","journal-title":"Microbiology"},{"key":"key20180919073709_B14","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically\u2014seventh edition","author":"Clinical and Laboratory Standards Institute","year":"2006"},{"key":"key20180919073709_B15","volume-title":"Performance standards for antimicrobial susceptibility testing; 19th informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2009"},{"key":"key20180919073709_B16","volume-title":"Clasificaci\u00f3n internacional de enfermedades: CIE 9 MC (7a ED)","author":"Ministerio de Sanidad y Consumo","year":"2010"},{"key":"key20180919073709_B17","doi-asserted-by":"crossref","unstructured":"RobertsJChandraMPebodyRStuartJ. 2007. Variation in incidence of pneumococcal and meningococcal disease across Europe. Euro Surveill. 12:pii=3310. http:\/\/www.eurosurveillance.org\/ViewArticle.aspx?ArticleId=3310.","DOI":"10.2807\/esw.12.46.03310-en"},{"key":"key20180919073709_B18","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1016\/j.vaccine.2010.03.069","article-title":"Surveillance of invasive pneumococcal disease in 30 EU countries: towards a European system?","volume":"28","author":"ECDC Country Experts for Pneumococcal Disease","year":"2010","journal-title":"Vaccine"},{"key":"key20180919073709_B19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10096-007-0294-4","article-title":"Reduction in pediatric invasive pneumococcal disease in the Basque Country and Navarre, Spain, after introduction of the heptavalent pneumococcal conjugate vaccine","volume":"26","author":"Aristegui","year":"2007","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"key20180919073709_B20","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/j.1469-0691.2006.1502_1.x","article-title":"Invasive pneumococcal disease among children in a health district of Barcelona: early impact of pneumococcal conjugate vaccine","volume":"12","author":"Spanish Pneumococcal Infection Study Network","year":"2006","journal-title":"Clin. Microbiol. Infect."},{"key":"key20180919073709_B21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/INF.0b013e318241d09e","article-title":"Clinical presentation of invasive pneumococcal disease in Spain in the era of heptavalent conjugate vaccine","volume":"31","author":"de Sevilla","year":"2012","journal-title":"Pediatr. Infect. Dis. J."},{"key":"key20180919073709_B22","first-page":"51","article-title":"Incidence of pneumococcal disease in the autonomous region of Madrid (1998\u20132006)","volume":"130","author":"Guti\u00e9rrez Rodr\u00edguez","year":"2008","journal-title":"Med. Clin. (Barc.)"},{"key":"key20180919073709_B23","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/jac\/dkp210","article-title":"Emergence of a multidrug-resistant clone (ST320) among invasive serotype 19A pneumococci in Spain","volume":"64","author":"Ardanuy","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"key20180919073709_B24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jinf.2009.05.012","article-title":"Emergence of invasive pneumococcal disease caused by multidrug-resistant serotype 19A among children in Barcelona","volume":"59","author":"Mu\u00f1oz-Almagro","year":"2009","journal-title":"J. Infect."},{"key":"key20180919073709_B25","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1016\/j.vaccine.2011.05.099","article-title":"Invasive pneumococcal disease: association between serotype, clinical presentation and lethality","volume":"29","author":"Rodr\u00edguez","year":"2011","journal-title":"Vaccine"},{"key":"key20180919073709_B26","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s10096-011-1468-7","article-title":"Serotype 3 is a common serotype causing invasive pneumococcal disease in children less than 5 years old, as identified by real-time PCR","volume":"31","author":"Selva","year":"2012","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"key20180919073709_B27","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1128\/JCM.01454-08","article-title":"Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007","volume":"47","author":"Fenoll","year":"2009","journal-title":"J. Clin. Microbiol."},{"key":"key20180919073709_B28","doi-asserted-by":"crossref","first-page":"9640","DOI":"10.1016\/j.vaccine.2011.10.038","article-title":"Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain)","volume":"29","author":"D\u00edez-Domingo","year":"2011","journal-title":"Vaccine"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1128\/CVI.00239-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:47:58Z","timestamp":1627591678000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00239-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,7]]},"references-count":28,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2013,9,26]]},"published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1128\/CVI.00239-13"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00239-13","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,7]]}}}